Clinical trials: PDAC
Pancreatic Cancer, Metastatic Pancreatic Cancer
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
Pancreatic cancer is difficult to diagnose early. By the time people have been diagnosed, the cancer has usually spread to other parts of the body (metastatic).
- Conditions
- Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
- Trial name
- NCT07409272
- Testing
- Setidegrasib, Oxaliplatin, Leucovorin
- Where
- 79 sites in United States, China and 4 more
- Volunteers
- 614 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Pancreatic Ductal Adenocarcinoma (PDAC)
Innovative Therapeutic Treatments to Inhibit Perineural Invasion in Pancreatic Adenocarcinoma
The overall goal of this project is to develop new therapeutic approaches to limit Perineural invasion (PNI) in pancreatic ductal adenocarcinoma (PDAC).
- Trial name
- PNIPDAC (NCT06616688)
- Testing
- Organoid-guided treatment
- Volunteers
- 50 people
- Sponsor
- IRCCS San Raffaele
Pancreatic Cancer
A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors
This Phase 1b/2 study will examine the effects of the study drugs, avelumab, binimetinib and talazoparib when given in a 2 (doublet) or 3 (triplet) drug combination, in patients with locally advanced or metastatic RAS-mutant…
- Trial name
- NCT03637491
- Testing
- Avelumab, Binimetinib, Talazoparib
- Where
- 18 sites in United States, Belgium and 1 more
- Volunteers
- 36 people
- Sponsor
- Pfizer
Solid Tumors
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
This is an open-label, multicenter Phase 2 study evaluating BMS-986504 in participants with advanced and/or metastatic solid tumors that have MTAP deletion.
- Trial name
- NCT07492680
- Testing
- BMS-986504, Daraxonrasib, Nivolumab + Relatlimab FDC
- Where
- 58 sites in United States, Belgium and 11 more
- Volunteers
- 260 people
- Sponsor
- Bristol-Myers Squibb
Pancreatic Ductal Adenocarcinoma
PRaG Therapy in Combination With Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) (NeoPRAG Study)
The goal of this clinical trial is to learn about Phase I+Phase II Clinical Study of PRaG Therapy in Combination With Chemotherapy (AG Regimen) for Neoadjuvant Treatment of Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)…
- Trial name
- NCT06345599
- Testing
- Radiotherapy, Immunotherapy:Granulocyte macrophage-colony stimulating factor(GM-CSF)、Cadumilimab, Chemotherapy:Albumin-bound paclitaxel、Gemcitabine
- Volunteers
- 66 people
- Sponsor
- Second Affiliated Hospital of Soochow University
Pancreatic Ductal Adenocarcinoma (PDAC)
Clinical Study of Radiotherapy Combined With Adebrelimab and NALIRIFOX for Conversion Therapy in Locally Advanced Pancreatic Cancer
This study intends to explore conversion therapy for locally advanced pancreatic cancer (LAPC). The intervention starts with modified stereotactic body radiation therapy (3-day regimen), followed by systemic therapy within 1-2…
- Trial name
- NCT07827053
- Testing
- Adebrelimab (PD-L1 inhibitor), NALIRIFOX, SBRT
- Volunteers
- 36 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Advanced or Metastatic Solid Tumors
A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors
This is an open-label, dose escalation and dose expansion study of MDK-703 as a monotherapy and in combination with other cancer therapies in adult study participants with advanced or metastatic solid tumors.
- Trial name
- ORCHID-1 (NCT05716295)
- Testing
- MDK-703, Checkpoint Inhibitor, Immune
- Where
- 6 sites in United States
- Volunteers
- 26 people
- Sponsor
- Medikine, Inc.
Metastatic Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Cancer
Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)
The main purpose of this study is to see how pancrelipase affects the body mass index (BMI) in people with metastatic PDAC. BMI is a measure based on a person's height and weight.
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma, Metastatic Pancreatic Carcinoma
- Trial name
- NCT05642962
- Testing
- Pertzye
- Where
- 7 sites in United States
- Volunteers
- 17 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Locally Advanced Pancreatic Adenocarcinoma
Surgery for Locally Unresectable Pancreatic Cancer
Pancreatic cancer is a severe disease often diagnosed at an advanced stage, when surgery is not possible. New chemotherapy treatments can sometimes shrink the tumor and make surgery an option.
- Trial name
- ROBIN (NCT07241663)
- Testing
- Questionnaire
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Azienda Ospedaliera di Padova
PDAC - Pancreatic Ductal Adenocarcinoma, FAP
Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma
This is a prospective, multi-center, single arm, open label, non-randomized study to evaluate the ability of [68Ga]FAPI-46 to detect FAP expressing cells in patients with resectable or borderline resectable PDAC.
- Trial name
- FAPI-46 PDAC (NCT05262855)
- Testing
- [68Ga]FAPI-46
- Where
- 4 sites in United States
- Volunteers
- 63 people
- Sponsor
- SOFIE
Pancreatic Adenocarcinoma Metastatic
Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy
The main goal of this study is to look at the effectiveness and anti-tumor activity (preventing growth of the tumor) of the drugs niraparib and ipilimumab, on the patients and their pancreatic cancer.
- Trial name
- ParpVax2 (NCT06747845)
- Testing
- Niraparib, FOLFIRI, Ipilimumab
- Where
- 2 sites in United States
- Volunteers
- 68 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Cancer of the Pancreas, Pancreatic Cancer
Clinical Validation of a Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer (VERIFI)
This is a case-control study to clinically validate the performance of PancreaSure, a protein biomarker test, to differentiate Stage I and Stage II pancreatic ductal adenocarcinoma (PDAC) patient samples from samples acquired…
- Conditions
- Cancer of the Pancreas, Pancreatic Cancer, Pancreas Neoplasms, Pancreatic Carcinoma Stage I
- Trial name
- VERIFI (NCT06947395)
- Testing
- PancreaSure
- Where
- 6 sites in United States
- Volunteers
- 386 people
- Sponsor
- Immunovia, Inc.
Pancreatic Adenocarcinoma
Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC)
Based on a central role of inflammation in pancreas cancer, the role of IL 1 in acute and chronic inflammation , the inhibitory effect of IL 1 alfa and beta by anakinra and preliminary experience with anakinra in combination with…
- Trial name
- NCT04926467
- Testing
- Anakinra
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Baylor Research Institute
Pancreatic Cancer, Pancreatic Cancer Metastatic
Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma
The purpose of this study is to evaluate the efficacy of combination therapy with two investigational RAS(ON) inhibitors (daraxonrasib and zoldonrasib) compared to chemotherapy.
- Conditions
- Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
- Trial name
- RASolute 309 (NCT07805954)
- Testing
- daraxonrasib, gemcitabine, nab-paclitaxel
- Where
- 5 sites in United States
- Volunteers
- 400 people
- Sponsor
- Revolution Medicines, Inc.
PDAC - Pancreatic Ductal Adenocarcinoma
Functional, Personalised and Integrated Profiling of Biopsied Pancreatic Tumours (CancerProfile by FNB)
Pancreatic ductal adenocarcinoma (PDAC) has the poorest prognosis of all digestive cancers due to lack of early diagnosis and limited response to treatment.
- Trial name
- NCT06666803
- Testing
- FNB sampling, blood sampling
- Where
- 2 sites in France
- Volunteers
- 60 people
- Sponsor
- IHU Strasbourg
Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC)
Advanced Therapies for Liver Metastases
Liver metastases (MTS) are the main cause of death for patients affected by colorectal carcinoma (CRC) and pancreatic ductal adenocarcinoma (PDAC), thus representing the major unmet clinical need for these malignancies.
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC), Liver Metastasis, IPMN, Pancreatic
- Trial name
- LiMeT (NCT04622423)
- Where
- Italy
- Volunteers
- 625 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
Glioblastoma Multiforme, Brain Neoplasms
Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.
This is a First-In-Human (FIH) study of [68Ga]-FF58 to characterize the imaging properties, safety, biodistribution and dosimetry properties of [68Ga]-FF58 in adults with relapsed or refractory (r/r) glioblastoma multiforme…
- Conditions
- Glioblastoma Multiforme, Brain Neoplasms, Gastroesophageal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT04712721
- Testing
- 68Ga-FF58
- Where
- 2 sites in France, Germany
- Volunteers
- 14 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Pancreatic Cancer
First-line Therapy in Metastatic PDAC
The overarching hypothesis of this trial is that the NAPOLI regimen and alternating cycles of NAPOLI and mFOLFOX6 (seq-NAPOLI-FOLFOX) are superior to the current standard of care gemcitabine/nab-paclitaxel.
- Trial name
- FOOTPATH (NCT03487016)
- Testing
- Gemcitabine, Nab-paclitaxel, 5-FU
- Where
- Germany
- Volunteers
- 270 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Pancreas Cancer, Pancreatic Carcinoma
Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC
The goal of this clinical trial is to test a new drug plus standard treatment compared with standard treatment alone in people with metastatic pancreatic ductal adenocarcinoma.
- Conditions
- Pancreas Cancer, Pancreatic Carcinoma, Pancreas Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
- Trial name
- FORTIFIDE (NCT06592664)
- Testing
- certepetide, nab-paclitaxel, gemcitabine
- Sponsor
- Lisata Therapeutics, Inc.
Pancreatic Cancer, Pancreatic Cancer Non-resectable
Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer
To evaluate the efficacy and safety of surufatinib combined with gemcitabine plus nab-paclitaxel in patients with locally advance d pancreatic cancer
- Conditions
- Pancreatic Cancer, Pancreatic Cancer Non-resectable, Pancreatic Ductal Adenocarcinoma, PDAC
- Trial name
- NCT06361030
- Testing
- surufatinib combined with gemcitabine plus nab-paclitaxel
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology